ChromaDex (CDXC) Stock Forecast & Price Target

ChromaDex Corp is poised for positive financial growth, with gross margins expected to improve into the mid-60s range, reflecting a substantial increase from the previous period's 61.8%. The company's flagship product, TRU NIAGEN, generated $22.7 million in sales, and an impressive increase in adjusted EBITDA from $1.3 million to $3.4 million signals enhanced profitability. Furthermore, the anticipated introduction of new lifestyle drug-like products, particularly NIAGEN IV, suggests that ChromaDex is entering a pivotal growth phase, supported by a favorable adjustment in revenue multiples.

ChromaDex Corp's financial outlook appears negative due to potential ongoing legal expenses that could significantly impair cash generation, raising concerns about the necessity for substantial capital raising. Additionally, unfavorable clinical data and adverse legal decisions could hinder the company's growth prospects, particularly in expanding its market presence outside the U.S. The inability to penetrate new markets, coupled with negative investor sentiment towards small-cap growth stocks, further exacerbates the risks associated with the company's future performance.